Crystalline glucosamine sulfate is the original glucosamine prescription product that has shown efficacy and safety in clinical trials in knee OA when used at a dose of 1500 mg once daily. In addition to the clinical data, its use is supported by a distinct pharmacologic profile and, most importantly, well described pharmacokinetics.

Physician and patient education on the differentiation of pCGS from other glucosamine formulations will help to improve treatment selection, increase treatment adherence, and optimize clinical benefit in OA.

Crystalline glucosamine sulfate (CGS; CAS number 216447-62-0) is a symptom-modifying drug with good evidence for favorable long-term effects on disease progression. CGS is a well-characterized substance containing glucosamine, sulfate, chloride, and sodium ions and showing tropism for articular cartilage [ 9 ].

Dona® is the original Crystalline Glucosamine Sulfate that has been shown effective in two 3-year controlled clinical studies. Dona® helps maintain the normal function of cartilage and supports healthy joint function, mobility, and flexibility.

In particular, long-term pivotal trials of crystalline glucosamine sulfate 1500 mg once daily have shown significant and clinically relevant improvement of pain and function limitation (symptom-modifying effect) in knee osteoarthritis.

2016年2月26日 · The dose-dependent effect of patented crystalline glucosamine sulfate on the IL-1β-induced gene expression of joint degeneration mediators MMP-3 (stromelysin-1) and ADAM-TS5 (aggrecanase 2) in human chondrocytes is optimized at …

2016年2月1日 · Glucosamine, in particular, is available as prescription patented crystalline glucosamine sulfate (pCGS) formulation (Rottapharm) [3], generic and over-the-counter (OTC) formulations of GS and food supplements mostly containing …

Glucosamine sulfate reverses the proinflammatory and joint-degenerating effects of interleukin-1 by inhibiting the cytokine intracellular signaling pathway. Clinical trials with the crystalline glucosamine sulfate.

Crystalline glucosamine sulfate administration resulted in pain reduction and joint function improvement, but the drug did not demonstrate structural efficacy, as it failed to delay knee OA progression.

In the present review of glucosamine for knee OA, we have investigated whether the evidence is greater for the patented crystalline glucosamine sulfate (pCGS) preparation (Rottapharm/Meda) than for other glucosamine formulations.